A PBPK Platform Model to Guide Intravenous and Subcutaneous Dosing for Bispecific T Cell Engagers

Topics Covered:
• Overview of the M-PBPK platform model development for Bispecific T cell engagers
• M-PBPK M&S strategies to include ontogeny changes to guide adult and paediatric IV and SC dosing
Certara accelerates medicines to patients using proprietary biosimulation software and technology to transform traditional drug discovery and development. Its clients include 1,600 global biopharmaceutical companies, leading academic institutions, and key regulatory agencies across 60 countries.
Please visit us at www.certara.com/